A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities – Erratum

Valentine Grumberg*, Stéphane Roze, Julie Chevalier, John Borrill, Anne-Françoise Gaudin and Sébastien Branchoux

Author for correspondence:
*Valentine Grumberg
E-mail: Valentine.grumberg@bms.com

DOI: https://doi.org/10.1017/S0266462322000125; Published online by Cambridge University Press March 25, 2022

In the original publication of Grumberg et al. (2022) a typesetting error occurred in Table 2. The correct Table 2 is reproduced below.

The publisher apologizes for this error.

Reference

Grumberg, V., **Roze, S.**, **Chevalier, J.**, **Borrill, J.**, **Gaudin, A.**, & **Branchoux, S.** (2022). A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities. *International Journal of Technology Assessment in Health Care*, **38**(1), E28. doi:10.1017/S0266462322000125

CAMBRIDGE
UNIVERSITY PRESS

Table 2. Best-Fit and Second Best-Fit Models to OS Kaplan–Meier Curves with at least 18-Month Extended Follow-up

Indication	RCC 2L	Melanoma 1L		NSCLC 2L			UC 1L
Study	CheckMate 025	CheckMate 066	KeyNote 006	KeyNote 010	CheckMate 057	CheckMate 017	KeyNote 045
Time horizon (mo)	120	120		120			60
Extrapolation used in the CE assessment report	Spline two-knots normal	HR over exponential	Unusual approach	KM + exponential	Log normal	Log logistic	KM+log logistic
RMST (mo)	36.10	39.35	48.04	25.55	23.03	22.40	20.02
Best-fit model	Log logistic	Generalized gamma	Generalized gamma	Log normal	Generalized gamma	Log logistic	Log normal
RSMT (mo)	41.42	56.37	55.34	35.25	25.99	21.09	28.27
Difference in RMST compared to extrapolation in the CE assessment report (mo)	5.3	17.0	7.3	9.7	3.0	−1.3	−1.7
Second best-fit model*	Log normal	Spline one-knot normal	Spline one-knot normal	Generalized gamma	Spline one-knot normal	Spline one-knot odds	Log logistic
RMST (mo)	42.17	55.73	54.72	37.50	25.60	23.06	18.00
Difference in RMST compared to extrapolation in the CE assessment report (mo)	6.1	16.4	6.7	12.0	2.6	0.6	−2.0

Abbreviations: HR: hazard ratio; KM: Kaplan-Meier; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma; RMST: restricted mean survival time; UC: urothelial cancer.